21:44 , Feb 12, 2019 |  BC Extra  |  Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
21:18 , Jan 9, 2019 |  BC Extra  |  Company News

Management tracks: Tak joins Flagship, Evercore taps Mehrotra

Paul-Peter Tak has stepped down from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to join Flagship Pioneering as a venture partner. He was GSK's SVP of R&D, chief immunology officer and development lead. Evercore ISI hired Ravi Mehrotra...
01:20 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim...
18:23 , Nov 9, 2018 |  BC Week In Review  |  Company News

Abeona gets rights to RegenxBio gene therapy vector

Gene therapy company RegenxBio Inc. (NASDAQ:RGNX) granted Abeona Therapeutics Inc. (NASDAQ:ABEO) exclusive, worldwide rights to use RegenxBio's NAV adeno-associated virus 9 (AAV9) vector to develop therapies for four lysosomal storage disorders. Abeona will pay RegenxBio...
22:35 , Oct 19, 2018 |  BC Extra  |  Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
22:41 , Jul 30, 2018 |  BC Extra  |  Company News

Management Tracks: Abeona, BioDelivery

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) hired Max Colao as chief commercial officer. He was SVP of U.S. commercial operations at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Allergy company DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) hired Kevin...
15:32 , May 25, 2018 |  BC Week In Review  |  Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...
23:26 , May 18, 2018 |  BC Extra  |  Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...
22:49 , Apr 3, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, Dermavant, Assembly

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) said President and CEO Timothy Miller will transition to president and CSO. He is succeeded as CEO by Carsten Thiel, who was EVP and chief commercial officer at...
19:39 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Abeona reports early data for AAV9 MPS IIIB gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) reported that its adeno-associated viral serotype 9 (AAV9)-based gene therapy ABO-101 was well tolerated with no treatment-related serious adverse events reported through day 30 in the first patient dosed in a...